Late-breaking abstract submission deadline
15th September 2021
This evening’s symposium will bring together a panel of leaders in the management of FMF who will inform on treatment paradigms that consider needs and expectations of patients.
Following the insightful presentations of the faculty members, there will be a live panel discussion, which will focus on FMF and the role anti-IL-1 therapy plays in its management. There will also be an opportunity for you to ask questions on this topic.
We hope that you enjoy the presentations and actively participate in what promises to be an interesting and lively program.
Welcome and opening remarks The road to optimizing FMF outcomes with anti-IL-1 therapy? |
Professor Marco Gattorno (Italy) |
FMF treatment goals Meeting and sustaining patient need |
Professor Eldad Ben-Chetrit (Israel) |
What are the treatment expectations for a patient with FMF Considering a holistic approach to achieve quality of life goals? |
Dr Véronique Hentgen (France) |
Anti IL-1 therapy treatment paradigms Live panel discussion: Summing it up Which one, when, and how? |
Professor Marco Gattorno (Italy) |
Live panel discussion: Summing it up FMF and placing anakinra in management? |
All |
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
© 2021 Swedish Orphan Biovitrum AB (publ) - All rights reserved
Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, Sweden
www.sobi.com
Date of preparation: May 2021
NP-16495
The International Society of Systemic Auto-Inflammatory Diseases (ISSAID) raise awareness, catalyse basic research and promote scientific and clinical knowledge on all aspects of systemic auto-inflammatory diseases.
ISSAID 2021 c/o MCI Geneva
9, rue du Pré-Bouvier
1242, Satigny, Geneva
Switzerland
Phone:
+41 22 33 99 673
E-mail: issaid@mci-group.com
Registration: issaid.reghot@mci-group.com
Abstracts: issaid.abs@mci-group.com
Official Website:
www.issaid.org